Literature DB >> 27619936

Emerging role of epithelial-mesenchymal transition in hepatic cancer.

Go J Yoshida1,2.   

Abstract

Accumulating evidence suggests that the phenomenon of epithelial-mesenchymal-transition (EMT) plays a fundamental role in the tumor development. Several research articles have been published from Journal of Experimental and Clinical Cancer Research (JECCR) which have investigated into the molecular machineries underlying the importance of EMT for hepatic cancer. Given those recent publications by JECCR, this commentary focuses on the pathological significance of EMT for liver tumor.

Entities:  

Keywords:  Cancer stem-like cells; Cirrhosis; Epithelial-mesenchymal transition; Hepatic cancer; Matrix metalloproteinases; Wnt/beta-catenin signal

Mesh:

Year:  2016        PMID: 27619936      PMCID: PMC5020508          DOI: 10.1186/s13046-016-0419-7

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


Commentary

Epithelial-mesenchymal transition (EMT) of cancer cells indicates the process in which epithelial cells lose their cell-cell adhesions and apicobasal polarity but also acquire more mesenchymal and invasive/metastatic phenotype [1]. While epithelial-typed proteins characterized by E-cadherin and cytokeratins are down-regulated, mesenchymal markers such as vimentin and N-cadherin are up-regulated. These genetic expression changes are regulated by EMT-inducing transcriptional factors (TFs) such as Snail, Slug, Twist, and ZEB1/2 [1]. Twist and Snail are regulated independently and act cooperatively to promote EMT of hepatocellular carcinoma (HCC) [2]. Furthermore, EMT is known to generate stromal-like cancer cells which acquire the invasion potential into the extracellular matrix mediated by matrix metalloproteinases (MMPs) expression. Xie et al. reported that the discoidin domain receptor 2 (DDR2) up-regulates MT1-MMP and MMP2 depending on ERK2/SNAIL1 axis in HCC [3]. Liver cancer includes primary hepatic neoplasms, which are distinct from the perspectives of both histological and molecular pathologies. Hepatic cancer is mainly classified into HCC, intrahepatic bile duct carcinoma (cholangiocarcinoma), and hepatoblastoma. HCC is the most prevalent among these heterogeneous kinds of hepatic cancer tissues. Chronic infection with hepatitis B and C virus, long-term alcohol consumption, aflatoxin-B1-contaminated food and obesity are the major causes of a late-stage of hepatic fibrosis, also referred to as cirrhosis [4]. Cirrhosis, composed of numerous regenerative nodules, leads to the development of HCC. It is sure that the regenerative nodules at the early stage are benign in nature. However, they are increasingly likely to transform into the dysplastic nodules, which correspond to the pre-malignant conditions [4]. Hepatocytes generally harbor the rapid cellular proliferation under both normal and inflammatory conditions. The rapid rate of cellular division under pathological conditions such as cirrhosis predisposes hepatic stem cells or normal proliferative hepatocytes to accumulate genetic and epigenetic alterations. Still, it remains to be unknown whether the origin of HCC is hepatic stem cells or differentiated hepatocytes. The molecular analysis of human HCC specimens has elucidated many genetic and epigenetic changes characterized by TP53, beta-catenin, E-cadherin, MET and its ligand hepatocyte growth factor, ErbB receptor family members, and cyclooxygenase 2 (COX2) [4]. Beta-catenin is a crucial downstream TF of the canonical Wnt signal pathway. When Wnt signal pathway is activated, Axin and adenomatous polyposis coli (APC) no longer bind to beta-catenin, resulting in the stabilization and the intra-nuclear translocation of the dissociated beta-catenin. Increased nuclear localization of beta-catenin has been frequently detected in human HCC samples [4, 5]. Wnt/beta-catenin signaling pathway regulates several genes governing cancer-relevant processes, including MYC, cyclin D1, COX2, and MMP7 [5]. Notably, Tang et al. have recently identified CTNND1 (delta-catenin) as a novel oncogene in HCC. The expression level of CTNND1 is positively correlated with invasiveness in human HCC specimens, and further, activates Wnt/beta-catenin signaling. Knockdown of CTNND1 expression surprisingly leads to mesenchymal-epithelial transition (MET), while overexpression results in EMT and enhances metastatic potential of HCC [6]. Du et al. revealed that Brachyury, which is highly conserved through evolution, promotes EMT of HCC via activation of Akt/mTOR signal pathway [7]. Brachyury belongs to the TFs within T-box and contributes to the formation of the midline of a bilaterian organism. Brachyury is expressed not only in the progenitor population throughout somitogenesis but also multiple types of human cancer such as lung and liver. Brachyury has been identified as an essential EMT regulator altering the expression level of E-cadherin and Slug [7]. In particular, there is the positive feedback machinery between Brachyury and TGF-beta in mesenchymal-like tumor cells, which have undergone EMT and up-regulated Brachyury [8]. Brachyury-overexpressed HCC cell lines undergo EMT with Akt activation, therefore promoting the metastasis, particularly the process of extravasation, colonization and the proliferation at the pre-metastatic niche [7]. Remarkably, EMT also contributes to the increased population of cancer stem-like cells (CSCs), which corresponds to the highly tumorigenic subpopulation of tumor cells existing at the top of the hierarchical tumor cell society [1, 9]. The enhanced emergence of CSCs due to EMT is expected to be responsible for tumor heterogeneity and therapeutic resistance [9]. For instance, Zhang et al. have recently demonstrated that the resistance to FOLFOX, the conventional anti-HCC chemotherapeutic regimen, is positively correlated with nestin expression, which leads to EMT and the increased number of CSCs associated with Wnt/beta-catenin activation [10]. Collectively, accumulating evidence has strongly suggested that the emerging roles of potentially therapeutic targets should be regarded as “silver bullets” against difficult-to-cure HCC cases.
  10 in total

Review 1.  Hepatocellular carcinoma pathogenesis: from genes to environment.

Authors:  Paraskevi A Farazi; Ronald A DePinho
Journal:  Nat Rev Cancer       Date:  2006-09       Impact factor: 60.716

Review 2.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

3.  Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma.

Authors:  Muh-Hwa Yang; Chih-Li Chen; Gar-Yang Chau; Shih-Hwa Chiou; Chien-Wei Su; Teh-Ying Chou; Wei-Li Peng; Jaw-Ching Wu
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

Review 4.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

5.  An autocrine loop between TGF-β1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype.

Authors:  Cecilia Larocca; Joseph R Cohen; Romaine I Fernando; Bruce Huang; Duane H Hamilton; Claudia Palena
Journal:  Mol Cancer Ther       Date:  2013-06-19       Impact factor: 6.261

6.  Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance.

Authors:  Yan Zhang; Shan Zeng; Junli Ma; Ganlu Deng; Yanlin Qu; Cao Guo; Hong Shen
Journal:  J Exp Clin Cancer Res       Date:  2016-07-13

7.  DDR2 facilitates hepatocellular carcinoma invasion and metastasis via activating ERK signaling and stabilizing SNAIL1.

Authors:  Binhui Xie; Weihao Lin; Junming Ye; Xiaonong Wang; Bing Zhang; Shiqiu Xiong; Heping Li; Guosheng Tan
Journal:  J Exp Clin Cancer Res       Date:  2015-09-11

8.  Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  Rui Du; Shanshan Wu; Xiaoning Lv; Henghu Fang; Sudong Wu; Jingbo Kang
Journal:  J Exp Clin Cancer Res       Date:  2014-12-14

9.  Overexpression of CTNND1 in hepatocellular carcinoma promotes carcinous characters through activation of Wnt/β-catenin signaling.

Authors:  Bo Tang; Fang Tang; Zhenran Wang; Guangying Qi; Xingsi Liang; Bo Li; Shengguang Yuan; Jie Liu; Shuiping Yu; Songqing He
Journal:  J Exp Clin Cancer Res       Date:  2016-05-18

Review 10.  Therapeutic strategies targeting cancer stem cells.

Authors:  Go J Yoshida; Hideyuki Saya
Journal:  Cancer Sci       Date:  2015-10-21       Impact factor: 6.716

  10 in total
  26 in total

1.  Epithelial-to-mesenchymal transition in FHC-silenced cells: the role of CXCR4/CXCL12 axis.

Authors:  I Aversa; F Zolea; C Ieranò; S Bulotta; A M Trotta; M C Faniello; C De Marco; D Malanga; F Biamonte; G Viglietto; G Cuda; S Scala; F Costanzo
Journal:  J Exp Clin Cancer Res       Date:  2017-08-03

2.  The prognostic values of the expression of Vimentin, TP53, and Podoplanin in patients with cervical cancer.

Authors:  Jiaying Lin; Jiaqi Lu; Chao Wang; Xiaohong Xue
Journal:  Cancer Cell Int       Date:  2017-09-07       Impact factor: 5.722

3.  Up-regulation of CDK16 by multiple mechanisms in hepatocellular carcinoma promotes tumor progression.

Authors:  Yitao Wang; Xian Qin; Tao Guo; Pengpeng Liu; Ping Wu; Zhisu Liu
Journal:  J Exp Clin Cancer Res       Date:  2017-07-17

4.  HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.

Authors:  Hong-Bo Huan; Da-Peng Yang; Xu-Dong Wen; Xue-Jiao Chen; Liang Zhang; Li-Li Wu; Ping Bie; Feng Xia
Journal:  J Exp Clin Cancer Res       Date:  2017-06-24

Review 5.  Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment.

Authors:  Go J Yoshida
Journal:  J Hematol Oncol       Date:  2017-03-09       Impact factor: 17.388

Review 6.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.

Authors:  Fanglong Wu; Jin Yang; Junjiang Liu; Ye Wang; Jingtian Mu; Qingxiang Zeng; Shuzhi Deng; Hongmei Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-06-10

7.  A novel prognostic models for identifying the risk of hepatocellular carcinoma based on epithelial-mesenchymal transition-associated genes.

Authors:  Chen Xiong; Guifu Wang; Dousheng Bai
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

8.  Hepatitis C virus NS3 protein enhances hepatocellular carcinoma cell invasion by promoting PPM1A ubiquitination and degradation.

Authors:  Yali Zhou; Yan Zhao; Yaoying Gao; Wenjun Hu; Yan Qu; Ning Lou; Ying Zhu; Xiaoping Zhang; Hongmei Yang
Journal:  J Exp Clin Cancer Res       Date:  2017-03-10

Review 9.  Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress.

Authors:  Zin W Myint; Gaurav Goel
Journal:  J Hematol Oncol       Date:  2017-04-24       Impact factor: 17.388

10.  MiR-144-3p promotes the tumor growth and metastasis of papillary thyroid carcinoma by targeting paired box gene 8.

Authors:  Chang Liu; Chang Su; Yanchun Chen; Guang Li
Journal:  Cancer Cell Int       Date:  2018-04-04       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.